Adlai Nortye Ltd. American Depositary Shares

Adlai Nortye Group Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of cancer therapies. Its pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. The RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. The immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Formerly known as Adlai Nortye Ltd., it changed its name to Adlai Nortye Group Ltd. in July 2026. Founded in 2004, the company is based in Singapore.